Table 3.
Neonatal outcomes of infants receiving early caffeine (1-2 DOL) and all infants with caffeine ≥3 DOL.
| Early caffeine (1-2 DOL) |
Caffeine after day 3 (≥3 DOL) |
p value | |
|---|---|---|---|
| N | 85 | 65 | |
| GA (wks) | 26.34 ± 1.84 | 26.28 ± 1.89 | p = 0.35 |
| BW (g) | 891.78 ± 227.50 | 888.08 ± 239.72 | p = 0.73 |
| Sex (female/male) | 38/47 (44.7%, 55.3%) | 37/28 (56.9%, 43.1%) | p = 0.27 |
|
| |||
| Short-term clinical assessment | |||
| Duration of NICU stay | 79.79 ± 30.51 | 75.72 ± 27.64 | p = 0.47 |
| BPD | 23 (27.1%) | 23 (35.1%) | p = 0.16 |
| ROP requiring surgery | 7 (8.2%) | 2 (3.1%) | p = 0.10 |
| RDS | 65 (76.5%) | 51 (78.5%) | p = 0.85 |
| PDA | 41 (48.2%) | 37 (56.9%) | p = 0.61 |
| PDA requiring ligation | 4 (4.7%) | 4 (6.2%) | p = 0.32 |
| Necrotizing enterocolitis | 8 (9.4%) | 8 (12.3%) | p = 1.00 |
| PVL | 4 (4.7%) | 2 (3.1%) | p = 0.27 |
DOL, days of life; BPD, bronchopulmonary dysplasia; ROP, retinopathy of prematurity; RDS, respiratory distress syndrome; PDA, patent ductus arteriosus; PVL, periventricular leukomalacia.